
eTable. Cox proportional hazards model with inverse probability of treatment weighting: predictors of in-hospital and 1-year mortality

eFigure. Flow diagram of study patients from the International Collaboration on Endocarditis–Prospective Cohort Study (ICE-PCS) database

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable.** Cox proportional hazards model with inverse probability of treatment weighting: predictors of in-hospital and 1-year mortality

<table>
<thead>
<tr>
<th>Variable</th>
<th>In Hospital Mortality (HR (95% CI))</th>
<th>1-Year Mortality (HR (95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early surgery</td>
<td>0.44 (0.38-0.52)</td>
<td>0.57 (0.49-0.67)</td>
</tr>
<tr>
<td>Age</td>
<td>1.02 (1.01-1.02)</td>
<td>1.02 (1.02-1.03)</td>
</tr>
<tr>
<td>Male gender</td>
<td>0.91 (0.78-1.07)</td>
<td>1.05 (0.89-1.22)</td>
</tr>
</tbody>
</table>
| Chronic illness 
  a Includes diabetes mellitus, cancer, immunosuppression, hemodialysis dependence, chronic obstructive pulmonary disease, cirrhosis, and other chronic comorbid conditions | 1.37 (1.17-1.61)                   | 1.34 (1.14-1.57)                |
| History of CHF prior to IE episode                | 0.71 (0.56-0.91)                   | 0.61 (0.48-0.78)                |
| Health care associated infection                  | 1.12 (0.95-1.33)                   | 1.37 (1.16-1.63)                |
| Coagulase negative staphylococcal infection       | 0.84 (0.66-1.07)                   | 1.01 (0.80-1.28)                |
| *Staphylococcus aureus* infection                 | 1.40 (1.15-1.71)                   | 1.50 (1.23-1.83)                |
| Viridans group streptococcal infection            | 0.84 (0.61-1.13)                   | 0.76 (0.55-1.04)                |
| Enterococcal infection                            | 0.98 (0.77-1.25)                   | 1.05 (0.82-1.34)                |
| Transesophageal echocardiography performed        | 0.47 (0.38-0.58)                   | 0.46 (0.38-0.57)                |
| Intracardiac vegetation                           | 1.73 (1.42-2.10)                   | 1.68 (1.38-2.05)                |
| Intracardiac abscess 
  b Based on transesophageal or transthoracic echocardiography | 1.82 (1.43-2.30)                   | 1.57 (1.24-1.99)                |
| Paravalvular complications 
  c Transesophageal or transthoracic echocardiographic evidence of paravalvular abscess or fistula formation | 1.38 (1.09-1.74)                   | 1.31 (1.05-1.64)                |
| Prosthetic valve complication 
  d Transesophageal or transthoracic echocardiographic evidence of dehiscence or severe regurgitation | 0.97 (0.82-1.15)                   | 1.06 (0.90-1.26)                |
| Systemic embolization 
  e Includes embolism to any major arterial vessel, excluding stroke | 1.33 (1.09-1.61)                   | 1.19 (0.98-1.45)                |
| Stroke                                            | 1.18 (0.99-1.41)                   | 1.65 (1.38-1.96)                |
| Persistent bacteremia                             | 1.11 (0.89-1.39)                   | 1.23 (0.97-1.55)                |
| Congestive heart failure                          | 1.92 (1.64-2.25)                   | 1.90 (1.62-2.23)                |

© 2013 American Medical Association. All rights reserved.
**eFigure.** Flow diagram of study patients from the International Collaboration on Endocarditis–Prospective Cohort Study (ICE-PCS) database.

1. **Definite a left or right-sided infective endocarditis**
   - 4166 patients

2. **Native valve endocarditis**
   - 1859 patients (67%)
   - **Non-native valve endocarditis** b
     - 345 patients (13%)

3. **Excluded cases: 39 patients (4%) c**
   - Missing values:
     - Gender – 3 patients
     - Receipt/date of surgery – 20 patients
     - In-hospital mortality – 3 patients
     - 1 year survival – 1 patient
     - Length of hospitalization – 5 patients
     - Days from admission to surgery > 100 – 7 patients

4. **Study population: Definite prosthetic valve endocarditis**
   - 1025 patients (96%)

5. **Early Surgery**
   - 490 patients (48%)

6. **Medical Therapy**
   - 535 patients (52%)

---

a Based on modified Duke criteria
b Includes device related endocarditis (e.g., pacemaker endocarditis)
c Exclusion of recurrence or relapse of IE